Todor Dentchev, MD
Medical Oncology · Grand Forks, NDNPI 1669563771
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,595 of the $10,961 with a category attached, or 60.2%. 5 manufacturers reported payments, led by AstraZeneca at 58.0% of the total. Reporting peaked in 2022 at $6,451 and has fallen 98.8% since, to $78 in 2025.
Across 14 payments — averaging $782.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Exelixis Inc.$3K
- Novartis$2K
- Pfizer$78
- Gilead$12
What the payments were for
- Consulting fees$6,59560%
- Speaking & faculty fees$3,09028%
- Travel & lodging$1,11810%
- Food & beverage$691%
- Education$901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 7 | $6,356 |
| Exelixis Inc. | 2 | $2,940 |
| Novartis | 1 | $1,575 |
| Pfizer | 3 | $78 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 17 | $276,895 |
| Lenalidomide | 15 | $211,273 |
| NubeqaDarolutamide | 13 | $206,375 |
| RevlimidLenalidomide | 14 | $186,022 |
| Abiraterone Acetate | 21 | $47,684 |
| Imatinib Mesylate | 11 | $3,028 |
| Anastrozole | 105 | $1,377 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $910 |
| Prochlorperazine Maleate | 68 | $890 |
| Letrozole | 45 | $689 |
| Ipratropium-AlbuterolIpratropium/Albuterol Sulfate | 11 | $671 |
| Acyclovir | 35 | $668 |
| Dexamethasone | 45 | $620 |
| Potassium Chloride | 16 | $587 |
| Tamoxifen Citrate | 22 | $583 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Grand Forks
- Chad PedersenWatford City$74K
- Mark GitauFargo$1K
- Bassim KobrossyFargo$439
- Patanit WatanaboonyakhetMinot$194
- John TateFargo$87
- Preston SteenFargo$44
- Denise SnowFargo$37
- Janet MacheledtFargo$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.